Cargando…

Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy

BACKGROUND: Based on data from two multicenter, phase III clinical trials (Studies 301 and 305), eribulin (a microtubule dynamics inhibitor) is indicated in the European Union (EU) for patients with locally advanced or metastatic breast cancer (MBC) after ≥1 prior chemotherapy for advanced disease,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pivot, X., Marmé, F., Koenigsberg, R., Guo, M., Berrak, E., Wolfer, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959925/ https://www.ncbi.nlm.nih.gov/pubmed/27177860 http://dx.doi.org/10.1093/annonc/mdw203

Ejemplares similares

Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine
por: Pivot, Xavier, et al.
Publicado: (2018)

Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis
por: Cortes, Javier, et al.
Publicado: (2019)

Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer
por: Coe, Faye, et al.
Publicado: (2021)

Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies
por: O’Shaughnessy, Joyce, et al.
Publicado: (2015)

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
por: Twelves, Chris, et al.
Publicado: (2014)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
por: Twelves, Chris, et al.
Publicado: (2015)

Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer
por: Kashiwagi, Shinichiro, et al.
Publicado: (2017)

Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
por: Shingaki, Sumito, et al.
Publicado: (2020)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
por: Wilks, Sharon, et al.
Publicado: (2015)

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
por: McIntyre, Kristi, et al.
Publicado: (2014)

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
por: McIntyre, Kristi, et al.
Publicado: (2014)

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life
por: Garrone, Ornella, et al.
Publicado: (2016)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy
por: Doherty, Mark K, et al.
Publicado: (2015)

Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Fleeman, Nigel, et al.
Publicado: (2019)

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience
por: Srinivasa, BJ, et al.
Publicado: (2018)

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study
por: Puhalla, Shannon, et al.
Publicado: (2016)

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
por: Muñoz-Couselo, Eva, et al.
Publicado: (2011)

Oncology Nursing Support for Safe and Effective Use of Eribulin in Metastatic Breast Cancer
por: Donovan, Diana, et al.
Publicado: (2014)

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide
por: Ro, Jungsil, et al.
Publicado: (2016)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy [Corrigendum]
Publicado: (2015)

Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer
por: Satomi-Tsushita, Natsuko, et al.
Publicado: (2019)

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2021)

Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2018)

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin
por: Lee, Suee, et al.
Publicado: (2015)

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer
por: Sakiyama, T, et al.
Publicado: (2015)

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea
por: Tremblay, Gabriel, et al.
Publicado: (2016)

Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan
por: Rau, Kun-Ming, et al.
Publicado: (2018)

Outcome of eribulin as a late treatment line for Thai metastatic breast cancer patients
por: Ditsatham, Chagkrit, et al.
Publicado: (2018)

Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice
por: Tanaka, Toshihiro, et al.
Publicado: (2017)

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Keenan, Tanya E., et al.
Publicado: (2021)

Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer
por: Chen, Pei-Hsin, et al.
Publicado: (2021)

Combination Chemotherapy of Mitomycin C and Methotrexate Was Effective on Metastatic Breast Cancer Resistant to Eribulin, Vinorelbine, and Bevacizumab after Anthracycline, Taxane, and Capecitabine
por: Tanabe, Masahiko
Publicado: (2016)

Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer
por: Zhao, Qi, et al.
Publicado: (2021)

Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan
por: Lin, Yu-Ju, et al.
Publicado: (2021)

Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer
por: Chalasani, Pavani, et al.
Publicado: (2021)

Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience − A Multicenter Retrospective Study
por: Jafri, Mariam, et al.
Publicado: (2022)

Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin
por: Bun, Ayako, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_80mbgjgf3ht2ghj0id368loshk